VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone.

Content Provider	Semantic Scholar
Author	Moise, Leonard Buller, R. Mark L. Schriewer, Jill Lee, Jae-Woo Frey, Sharon E. Weiner, David B. Martin, William Groot, Anne S. De
Copyright Year	2011
Abstract	The potential for smallpox to be disseminated in a bioterror attack has prompted development of new, safer smallpox vaccination strategies. We designed and evaluated immunogenicity and efficacy of a T-cell epitope vaccine based on conserved and antigenic vaccinia/variola sequences, identified using bioinformatics and immunological methods. Vaccination in HLA transgenic mice using a DNA-prime/peptide-boost strategy elicited significant T cell responses to multiple epitopes. No antibody response pre-challenge was observed, neither against whole vaccinia antigens nor vaccine epitope peptides. Remarkably, 100% of vaccinated mice survived lethal vaccinia challenge, demonstrating that protective immunity to vaccinia does not require B cell priming.
File Format	PDF HTM / HTML
DOI	10.1016/j.vaccine.2010.10.064
PubMed reference number	21055490
Journal	Medline
Volume Number	29
Issue Number	3
Alternate Webpage(s)	https://digitalcommons.uri.edu/cgi/viewcontent.cgi?article=1090&context=immunology_facpubs
Alternate Webpage(s)	https://doi.org/10.1016/j.vaccine.2010.10.064
Journal	Vaccine
Language	English
Access Restriction	Open
Content Type	Text
Resource Type	Article